OCD Treatment – mycolab.ai

A Novel, Non-Hallucinogenic Psychedelic for the Treatment of OCD and Tic Disorder

mycolabadmin

Researchers developed a new drug called HBL20017 based on psychedelic compounds that does not cause hallucinations. In animal tests, this drug significantly reduced obsessive behaviors and involuntary muscle twitches, suggesting it could treat conditions like obsessive-compulsive disorder and Tourette’s syndrome. A single dose showed beneficial effects that lasted up to 42 days, and the compound appeared safer than existing psychedelic treatments.

PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity

mycolabadmin

This study is investigating whether psilocybin (an active compound in magic mushrooms) can help people with obsessive-compulsive disorder (OCD) by improving their mental flexibility and brain plasticity. Participants will receive two doses of psilocybin—a low test dose and a slightly higher therapeutic dose—four weeks apart, while receiving professional psychological support. Researchers will measure changes in cognitive abilities and brain activity to understand how psilocybin might help reduce OCD symptoms like intrusive thoughts and repetitive behaviors.

Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming

mycolabadmin

Researchers tested whether psilocybin (the active compound in magic mushrooms) could treat obsessive-compulsive disorder using genetically modified mice that exhibit excessive grooming similar to OCD in humans. A single dose of psilocybin or psychedelic mushroom extract significantly reduced the excessive grooming behavior and anxiety in these mice, with benefits lasting up to six weeks. These findings suggest psilocybin may be a promising new treatment for OCD in humans, offering longer-lasting effects from a single dose compared to current medications.

Research Topic: OCD Treatment

A Novel, Non-Hallucinogenic Psychedelic for the Treatment of OCD and Tic Disorder

PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity

Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming